GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
Alex Rose confirmed as Multitude Bank’s new Chief Operations Officer
Alex Rose's appointment receives MFSA regulatory approval.
Pitbull concert ‘was a testament to how far our country has come’ – Mark Grech
On Sunday, American performer Pitbull rocked Ta' Qali with his famous hits.
‘At some point sales will fall’: Norman Aquilina cautions on grocery retail sector growth
'More stores do not create more demand, they simply redistribute existing spend across a larger base,' he says.
Atlantis Management appoints Anndrea Moran as Head of Legal
She serves as an Executive Committee Member of the Malta Maritime Law Association.
